254 related articles for article (PubMed ID: 11396639)
1. CD79: a review.
Chu PG; Arber DA
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):97-106. PubMed ID: 11396639
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
[TBL] [Abstract][Full Text] [Related]
3. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.
Korkolopoulou P; Cordell J; Jones M; Kaklamanis L; Tsenga A; Gatter KC; Mason DY
Histopathology; 1994 Jun; 24(6):511-5. PubMed ID: 7520411
[TBL] [Abstract][Full Text] [Related]
4. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
[TBL] [Abstract][Full Text] [Related]
5. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.
Dworzak MN; Fritsch G; Fröschl G; Printz D; Gadner H
Blood; 1998 Nov; 92(9):3203-9. PubMed ID: 9787156
[TBL] [Abstract][Full Text] [Related]
6. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains.
Vuillier F; Dumas G; Magnac C; Prevost MC; Lalanne AI; Oppezzo P; Melanitou E; Dighiero G; Payelle-Brogard B
Blood; 2005 Apr; 105(7):2933-40. PubMed ID: 15591116
[TBL] [Abstract][Full Text] [Related]
7. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.
Kanavaros P; Gaulard P; Charlotte F; Martin N; Ducos C; Lebezu M; Mason DY
Am J Pathol; 1995 Mar; 146(3):735-41. PubMed ID: 7887454
[TBL] [Abstract][Full Text] [Related]
8. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.
Yao X; Teruya-Feldstein J; Raffeld M; Sorbara L; Jaffe ES
Mod Pathol; 2001 Feb; 14(2):105-10. PubMed ID: 11235901
[TBL] [Abstract][Full Text] [Related]
9. Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).
Gordon MS; Kanegai CM; Doerr JR; Wall R
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4126-31. PubMed ID: 12651942
[TBL] [Abstract][Full Text] [Related]
10. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
Mason DY; Cordell JL; Brown MH; Borst J; Jones M; Pulford K; Jaffe E; Ralfkiaer E; Dallenbach F; Stein H
Blood; 1995 Aug; 86(4):1453-9. PubMed ID: 7632952
[TBL] [Abstract][Full Text] [Related]
11. CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity.
Barakzai MA; Pervez S
Indian J Pathol Microbiol; 2009; 52(1):6-9. PubMed ID: 19136769
[TBL] [Abstract][Full Text] [Related]
12. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
13. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
Browne P; Petrosyan K; Hernandez A; Chan JA
Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders.
McCarron KF; Hammel JP; Hsi ED
Am J Clin Pathol; 2000 Jun; 113(6):805-13. PubMed ID: 10874881
[TBL] [Abstract][Full Text] [Related]
15. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.
Tzankov A; Zimpfer A; Pehrs AC; Lugli A; Went P; Maurer R; Pileri S; Dirnhofer S
Mod Pathol; 2003 Nov; 16(11):1141-7. PubMed ID: 14614054
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Ig-associated heterodimer (mb-1 and B29) in Hodgkin's disease.
Kuzu I; Delsol G; Jones M; Gatter KC; Mason DY
Histopathology; 1993 Feb; 22(2):141-4. PubMed ID: 8454258
[TBL] [Abstract][Full Text] [Related]
17. Zebrafish B Cell Development without a Pre-B Cell Stage, Revealed by CD79 Fluorescence Reporter Transgenes.
Liu X; Li YS; Shinton SA; Rhodes J; Tang L; Feng H; Jette CA; Look AT; Hayakawa K; Hardy RR
J Immunol; 2017 Sep; 199(5):1706-1715. PubMed ID: 28739882
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells.
Hashimoto S; Chiorazzi N; Gregersen PK
Mol Immunol; 1995 Jun; 32(9):651-9. PubMed ID: 7643857
[TBL] [Abstract][Full Text] [Related]
19. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
Kozlov I; Beason K; Yu C; Hughson M
Cancer Genet Cytogenet; 2005 Nov; 163(1):62-7. PubMed ID: 16271957
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K; Bai B; Hilden VI; Bollum LK; Våtsveen TK; Munthe LA; Smeland EB; Irish JM; Wälchli S; Myklebust JH
J Immunol; 2022 Nov; 209(10):2042-2053. PubMed ID: 36426942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
